LIVE

EWTX

Edgewise Therapeutics, Inc.

EWTX

NASDAQ·Healthcare·Biotechnology·Mkt cap $4.2B

$39.56

▲ +1.05%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$12.30 - $43.93

P/E

-23.83

Fwd P/E

-20.36

Beta

0.30

Div Yield

0.00%

Avg Vol

1.4M

Shares Out

107.3M

Mkt Cap

$4.2B

Price action

Price chart

Up 200.9% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • First-in-class mechanism targeting root cause of dystrophinopathies rather than symptomatic treatment
  • Precision medicine approach enabling targeted therapy development for genetically defined disorders
  • Experienced management team with deep expertise in muscle biology and rare disease drug development
  • Orphan drug designation providing regulatory incentives and market exclusivity opportunities
▼

Bear Case

1 risk

  • Low volatility (beta 0.3).

Growth

Revenue decline expected

Clinical development progression of EDG-5506 through Phase 2 and potential Phase 3 trials

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Strong

+17.5% over 3m

Quality

Loss-making

Mixed fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: May 6, 2026

“
Q2 26 RECAP

MAY 7, 2026

Reported EPS of -$0.46 vs -$0.50 consensus (+8.0% surprise).

EPS beat +8.0%

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+8.0%

Next: May 6, 2026

Revenue trend · last 8Q

—

—

—

—

—

—

—

—

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

View full earnings history →

Wall Street consensus

6 analysts · 83% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

5

83%

Hold

1

17%

Sell

0%

Median Price Target

$52.00

▲ +31.4% vs $39.56

Low $45.00
Median $52.00
High $66.00

Latest: Goldman Sachs · Jun 17, 2026

5 analysts covering

View full analyst page →

vs Industry

How EWTX stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.